Comparing central line versus peripheral blood draws for heparin anti-Xa using syringe or vacuum flush
Official title: Central Catheter Anti-Xa Sampling Study for Accurate aNalysis and Reliable Dosage Assessment
Run by Centre Hospitalier Régional d'Orléans · NCT07183605 · Data updated 2026-11-12
This test sees if blood taken from a central line with a 5 mL syringe flush or a vacuum tube discard gives the same heparin anti‑Xa result as a standard peripheral vein draw in ICU patients on continuous heparin.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Centre Hospitalier Régional d'Orléans Academic / other |
| Locations | 1 site (Orléans) |
| Status | Recruiting |
| Started | September 22, 2025 |
| Main results expected | September 2026 |
| Study ends | October 2026 |
| Registry record updated | November 25, 2025 |
| Trial ID | NCT07183605 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) in the ICU with a multi-lumen central venous catheter who are receiving continuous IV unfractionated heparin targeting anti‑Xa 0.3–0.7 IU/mL are ideal candidates.
✕Probably not a fit
Patients without a central catheter, those not on continuous unfractionated heparin, pregnant or breastfeeding individuals, and persons under legal protection are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center comparison enrolling ICU patients who have a multi-lumen central venous catheter and are receiving continuous unfractionated heparin. For each participant, four paired blood samples will be collected simultaneously: one from a peripheral vein (reference) and one from the central catheter using one of two randomized flushing techniques (a 5 mL syringe flush over 5 seconds or a 5 mL vacuum-tube discard). A three-way stopcock is used to temporarily pause the heparin infusion during sampling to reduce contamination risk. The primary outcome is concordance of anti‑Xa activity measurements between central-catheter and peripheral samples across the two flushing methods.
Why it matters
Potential benefit: If successful, patients could avoid repeated peripheral venipunctures because reliable anti‑Xa monitoring could be done from existing central lines.
How similar studies have gone: Some prior single-center reports suggest central-line samples can match peripheral results for certain lab tests, but specific data on anti‑Xa with these two flushing methods are limited, so this approach is relatively novel for anti‑Xa monitoring.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Person (or support person/relative if unable to do so) who has agreed to participate in the study * 18 years of age or older * Hospitalized in intensive care medicine * Having a central venous catheter with at least three lumens (internal jugular, subclavian or femoral) already in place * Receiving continuous intravenous unfractionned heparin, with target Anti-Xa activity between 0.3 and 0.7 IU/ml. Exclusion Criteria: * Protected person (under guardianship or curatorship) * Person under court protection * Person deprived of liberty * Person not affiliated to the French social security * Pregnant or breast-feeding woman
Where it's running
-
Chu Orleans
Orléans, France Recruiting
Study contacts
- Principal investigator: Gregoire MULLER, Dr — CHU Orléans
- Study coordinator: Gregoire MULLER, Dr
- Email: gregoire.muller@chu-orleans.fr
- Phone: +33238229534
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LMWH versus UFH for ECMO anticoagulation during bilateral lung transplant
This will see if low-molecular-weight heparin (enoxaparin) works as a safe and effective alternative to unfractionated heparin for blood thinning during ECMO around bilateral lung transplantation.
-
Evaluating caudal analgesia in patients on anticoagulants
This study is testing whether a pain relief method called caudal analgesia can be safely used in patients on blood thinners without causing serious problems.
-
Iron status prediction in elderly with inflammation
This study tests a model to tell true iron deficiency from inflammation-related anemia in people aged 75 and older who are hospitalized with inflammation.
-
Can CZT-SPECT/CT quantify myocardial tracer uptake to match PET measurements in coronary artery disease?
This study tests whether CZT-SPECT/CT can quantify heart blood flow at rest and stress and see if the results align with PET measurements for people with coronary artery disease.
-
Cold plasma treatment for chronic wounds in adults
This study tests whether cold plasma applied with helium and dressings infused with plasma-induced ions can help healing in adults with chronic leg or other vascular wounds.
-
Does handedness affect how well the arm recovers after a stroke?
This study checks if being left- or right-handed before a recent stroke influences how smoothly the arm recovers motor skills over six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.